SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Rocket Pharmaceuticals

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Rocket Pharmaceuticals due to misleading statements regarding the safety of its clinical trial for RP-A501, which led to significant investor losses [3][5][6]. Group 1: Legal Investigation and Claims - Faruqi & Faruqi is encouraging investors who suffered losses exceeding $50,000 in Rocket Pharmaceuticals between February 27, 2025, and May 26, 2025, to discuss their legal options [1]. - The firm reminds investors of the August 11, 2025, deadline to seek the role of lead plaintiff in a federal securities class action against Rocket Pharmaceuticals [3]. - The complaint alleges that Rocket Pharmaceuticals provided positive statements while concealing material adverse facts about the safety of RP-A501 and the clinical trial protocol [5]. Group 2: Clinical Trial Issues - Rocket Pharmaceuticals faced a clinical hold from the FDA on the RP-A501 Phase 2 pivotal study after a patient suffered a Serious Adverse Event (SAE), which ultimately resulted in death [6]. - The company amended the trial protocol to introduce a new immunomodulatory agent without disclosing this critical update to investors, which is a key point of contention in the lawsuit [5][6]. Group 3: Stock Price Impact - Following the announcement of the clinical hold, Rocket's stock price plummeted from $6.27 per share on May 23, 2025, to $2.33 per share on May 27, 2025, marking a decline of approximately 37% in just one trading day [8].